Concepts (268)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mental Disorders | 5 | 2026 | 60 | 2.570 |
Why?
|
| Resilience, Psychological | 2 | 2026 | 12 | 1.640 |
Why?
|
| Adult | 32 | 2026 | 2113 | 1.130 |
Why?
|
| Social Stigma | 2 | 2026 | 58 | 1.110 |
Why?
|
| Cross-Sectional Studies | 15 | 2026 | 506 | 1.100 |
Why?
|
| Male | 38 | 2026 | 3671 | 1.080 |
Why?
|
| Humans | 47 | 2026 | 6794 | 1.000 |
Why?
|
| Female | 40 | 2026 | 4060 | 0.990 |
Why?
|
| Self Efficacy | 2 | 2025 | 18 | 0.940 |
Why?
|
| Nutrition Surveys | 12 | 2021 | 67 | 0.930 |
Why?
|
| Middle Aged | 30 | 2026 | 2108 | 0.930 |
Why?
|
| Young Adult | 13 | 2026 | 567 | 0.770 |
Why?
|
| Self Report | 2 | 2025 | 35 | 0.760 |
Why?
|
| Aged | 26 | 2024 | 1539 | 0.710 |
Why?
|
| United States | 21 | 2024 | 1019 | 0.660 |
Why?
|
| Kefir | 1 | 2020 | 3 | 0.630 |
Why?
|
| Lactobacillus | 1 | 2020 | 6 | 0.630 |
Why?
|
| Oxidative Stress | 2 | 2020 | 102 | 0.620 |
Why?
|
| Probiotics | 1 | 2020 | 10 | 0.620 |
Why?
|
| Aging | 2 | 2020 | 105 | 0.610 |
Why?
|
| Brain | 1 | 2020 | 94 | 0.610 |
Why?
|
| Prevalence | 14 | 2024 | 259 | 0.600 |
Why?
|
| Cardiovascular Diseases | 4 | 2017 | 172 | 0.590 |
Why?
|
| Liver | 1 | 2020 | 157 | 0.590 |
Why?
|
| Accelerometry | 1 | 2017 | 3 | 0.550 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 6 | 0.540 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2017 | 35 | 0.520 |
Why?
|
| Thiazolidinediones | 1 | 2017 | 39 | 0.520 |
Why?
|
| Exercise | 1 | 2017 | 55 | 0.520 |
Why?
|
| Diabetes Mellitus | 4 | 2016 | 208 | 0.480 |
Why?
|
| Hospitalization | 3 | 2021 | 128 | 0.480 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 165 | 0.470 |
Why?
|
| Population Surveillance | 2 | 2013 | 30 | 0.460 |
Why?
|
| Health Transition | 1 | 2014 | 3 | 0.420 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 279 | 0.420 |
Why?
|
| Glycated Hemoglobin A | 1 | 2014 | 65 | 0.410 |
Why?
|
| Accidents, Traffic | 1 | 2013 | 14 | 0.410 |
Why?
|
| Brain Injuries | 1 | 2013 | 12 | 0.410 |
Why?
|
| Healthcare Disparities | 2 | 2025 | 83 | 0.390 |
Why?
|
| Psychometrics | 2 | 2024 | 14 | 0.390 |
Why?
|
| Glaucoma | 2 | 2024 | 103 | 0.380 |
Why?
|
| Multiple Sclerosis | 2 | 2026 | 5 | 0.370 |
Why?
|
| Health Status Disparities | 2 | 2025 | 83 | 0.370 |
Why?
|
| Adolescent | 13 | 2021 | 869 | 0.360 |
Why?
|
| California | 11 | 2023 | 230 | 0.330 |
Why?
|
| Albuminuria | 3 | 2020 | 31 | 0.320 |
Why?
|
| Length of Stay | 2 | 2021 | 53 | 0.300 |
Why?
|
| Self-Injurious Behavior | 2 | 2018 | 8 | 0.270 |
Why?
|
| Suicide, Attempted | 2 | 2018 | 14 | 0.260 |
Why?
|
| Age Factors | 5 | 2021 | 193 | 0.260 |
Why?
|
| Birth Weight | 1 | 2007 | 33 | 0.260 |
Why?
|
| Intraocular Pressure | 2 | 2024 | 127 | 0.260 |
Why?
|
| Retrospective Studies | 8 | 2024 | 681 | 0.250 |
Why?
|
| Sex Factors | 5 | 2021 | 155 | 0.250 |
Why?
|
| Cohort Studies | 3 | 2017 | 285 | 0.240 |
Why?
|
| Social Participation | 1 | 2026 | 1 | 0.240 |
Why?
|
| Hospital Mortality | 3 | 2021 | 36 | 0.240 |
Why?
|
| Adaptation, Psychological | 1 | 2026 | 35 | 0.240 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 280 | 0.230 |
Why?
|
| Stomach Neoplasms | 2 | 2016 | 11 | 0.230 |
Why?
|
| Metabolic Syndrome | 2 | 2020 | 35 | 0.230 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 112 | 0.220 |
Why?
|
| Severity of Illness Index | 1 | 2025 | 118 | 0.220 |
Why?
|
| Rural Population | 1 | 2024 | 16 | 0.220 |
Why?
|
| Global Health | 1 | 2025 | 54 | 0.220 |
Why?
|
| Risk Factors | 9 | 2024 | 767 | 0.220 |
Why?
|
| Academies and Institutes | 1 | 2024 | 8 | 0.220 |
Why?
|
| Glaucoma, Neovascular | 1 | 2024 | 7 | 0.210 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2024 | 24 | 0.210 |
Why?
|
| Registries | 1 | 2024 | 63 | 0.210 |
Why?
|
| Ophthalmology | 1 | 2024 | 39 | 0.210 |
Why?
|
| Veterans | 1 | 2024 | 70 | 0.210 |
Why?
|
| Iron | 2 | 2015 | 35 | 0.200 |
Why?
|
| Psychotic Disorders | 1 | 2023 | 9 | 0.200 |
Why?
|
| Animals | 5 | 2020 | 1875 | 0.200 |
Why?
|
| Xylans | 2 | 2016 | 33 | 0.200 |
Why?
|
| Mexican Americans | 2 | 2021 | 14 | 0.190 |
Why?
|
| Optometrists | 1 | 2022 | 2 | 0.190 |
Why?
|
| Ophthalmologists | 1 | 2022 | 3 | 0.190 |
Why?
|
| Hypertension | 5 | 2016 | 147 | 0.190 |
Why?
|
| Neck Injuries | 2 | 2019 | 7 | 0.190 |
Why?
|
| Vision, Low | 1 | 2022 | 10 | 0.180 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2023 | 76 | 0.180 |
Why?
|
| Aged, 80 and over | 7 | 2016 | 497 | 0.180 |
Why?
|
| Education, Distance | 1 | 2022 | 3 | 0.180 |
Why?
|
| Mental Health | 2 | 2024 | 70 | 0.180 |
Why?
|
| Biomarkers | 2 | 2020 | 214 | 0.180 |
Why?
|
| Pregnancy Complications | 2 | 2017 | 44 | 0.180 |
Why?
|
| Adenocarcinoma | 2 | 2019 | 50 | 0.180 |
Why?
|
| Hospital Charges | 1 | 2021 | 5 | 0.170 |
Why?
|
| Factor Analysis, Statistical | 1 | 2021 | 3 | 0.170 |
Why?
|
| Schizophrenia | 1 | 2021 | 9 | 0.170 |
Why?
|
| Child | 4 | 2021 | 524 | 0.170 |
Why?
|
| Fatty Liver | 1 | 2021 | 59 | 0.170 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 36 | 0.160 |
Why?
|
| Mice | 2 | 2020 | 746 | 0.160 |
Why?
|
| Morbidity | 2 | 2017 | 21 | 0.160 |
Why?
|
| Inflammation Mediators | 1 | 2020 | 30 | 0.160 |
Why?
|
| Infant, Newborn | 2 | 2013 | 199 | 0.160 |
Why?
|
| Lipid Peroxidation | 1 | 2020 | 11 | 0.160 |
Why?
|
| Substance-Related Disorders | 2 | 2018 | 102 | 0.150 |
Why?
|
| Bicycling | 1 | 2019 | 4 | 0.150 |
Why?
|
| Injury Severity Score | 1 | 2019 | 7 | 0.150 |
Why?
|
| Head Protective Devices | 1 | 2019 | 4 | 0.150 |
Why?
|
| Craniocerebral Trauma | 1 | 2019 | 10 | 0.150 |
Why?
|
| Risk | 2 | 2017 | 43 | 0.150 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2019 | 9 | 0.150 |
Why?
|
| African Americans | 3 | 2014 | 264 | 0.150 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2019 | 18 | 0.150 |
Why?
|
| Carcinoma, Ehrlich Tumor | 1 | 2019 | 11 | 0.150 |
Why?
|
| Apoptosis | 2 | 2019 | 179 | 0.140 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 38 | 0.130 |
Why?
|
| Patient Admission | 1 | 2017 | 10 | 0.130 |
Why?
|
| Socioeconomic Factors | 5 | 2021 | 197 | 0.120 |
Why?
|
| Automobile Driving | 1 | 2016 | 10 | 0.120 |
Why?
|
| Databases, Factual | 5 | 2019 | 81 | 0.120 |
Why?
|
| Stomach | 1 | 2016 | 8 | 0.120 |
Why?
|
| Carcinogenesis | 1 | 2016 | 11 | 0.120 |
Why?
|
| Text Messaging | 1 | 2016 | 14 | 0.120 |
Why?
|
| Intention | 1 | 2016 | 20 | 0.120 |
Why?
|
| Dementia, Vascular | 1 | 2016 | 6 | 0.120 |
Why?
|
| Inpatients | 1 | 2016 | 22 | 0.120 |
Why?
|
| Pregnancy | 4 | 2017 | 599 | 0.120 |
Why?
|
| Infant | 2 | 2013 | 187 | 0.120 |
Why?
|
| Alzheimer Disease | 1 | 2016 | 30 | 0.120 |
Why?
|
| Kidney Diseases | 3 | 2006 | 121 | 0.110 |
Why?
|
| Child, Preschool | 2 | 2013 | 258 | 0.110 |
Why?
|
| Protective Agents | 1 | 2015 | 4 | 0.110 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 10 | 0.110 |
Why?
|
| Vitamin D Deficiency | 2 | 2005 | 24 | 0.110 |
Why?
|
| Medical History Taking | 1 | 2014 | 8 | 0.110 |
Why?
|
| Shock, Septic | 1 | 2014 | 4 | 0.110 |
Why?
|
| Elective Surgical Procedures | 1 | 2014 | 5 | 0.110 |
Why?
|
| Neurosurgical Procedures | 1 | 2014 | 6 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2014 | 9 | 0.100 |
Why?
|
| Medicare | 3 | 2023 | 57 | 0.100 |
Why?
|
| Comorbidity | 3 | 2021 | 147 | 0.100 |
Why?
|
| Diabetes Complications | 1 | 2014 | 41 | 0.100 |
Why?
|
| Pregnancy in Diabetics | 1 | 2013 | 8 | 0.100 |
Why?
|
| Diabetes, Gestational | 1 | 2013 | 14 | 0.100 |
Why?
|
| Radiation Tolerance | 1 | 2013 | 5 | 0.100 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 5 | 0.100 |
Why?
|
| Radiation Injuries | 1 | 2013 | 9 | 0.100 |
Why?
|
| Blood Glucose | 1 | 2014 | 188 | 0.100 |
Why?
|
| Blood Pressure | 2 | 2003 | 112 | 0.090 |
Why?
|
| Hearing Loss, Noise-Induced | 1 | 2012 | 5 | 0.090 |
Why?
|
| Health Services Accessibility | 2 | 2025 | 145 | 0.090 |
Why?
|
| Patient Discharge | 3 | 2007 | 27 | 0.090 |
Why?
|
| Odds Ratio | 4 | 2018 | 82 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2003 | 145 | 0.090 |
Why?
|
| Health Surveys | 3 | 2007 | 75 | 0.090 |
Why?
|
| Los Angeles | 2 | 2017 | 321 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2010 | 34 | 0.080 |
Why?
|
| Reference Values | 2 | 2007 | 56 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 2 | 2014 | 420 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2010 | 63 | 0.080 |
Why?
|
| Incidence | 2 | 2023 | 197 | 0.070 |
Why?
|
| Cholesterol, LDL | 2 | 2024 | 35 | 0.070 |
Why?
|
| Parity | 1 | 2007 | 7 | 0.070 |
Why?
|
| Insurance Coverage | 1 | 2007 | 14 | 0.070 |
Why?
|
| Gestational Age | 1 | 2007 | 58 | 0.060 |
Why?
|
| Databases as Topic | 1 | 2007 | 9 | 0.060 |
Why?
|
| Insurance, Health | 1 | 2007 | 26 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2007 | 56 | 0.060 |
Why?
|
| Vitamin D | 1 | 2007 | 45 | 0.060 |
Why?
|
| Hypoglycemia | 1 | 2007 | 30 | 0.060 |
Why?
|
| Lipids | 1 | 2006 | 35 | 0.060 |
Why?
|
| Atherosclerosis | 1 | 2006 | 39 | 0.060 |
Why?
|
| Poverty | 1 | 2006 | 64 | 0.060 |
Why?
|
| Methylnitronitrosoguanidine | 2 | 2016 | 6 | 0.060 |
Why?
|
| Rats, Wistar | 2 | 2016 | 55 | 0.060 |
Why?
|
| Pregnancy Outcome | 2 | 2017 | 42 | 0.060 |
Why?
|
| Population Groups | 1 | 2005 | 5 | 0.060 |
Why?
|
| Pregnancy, Ectopic | 1 | 2005 | 6 | 0.060 |
Why?
|
| Hip Fractures | 1 | 2005 | 9 | 0.060 |
Why?
|
| Skilled Nursing Facilities | 1 | 2005 | 7 | 0.060 |
Why?
|
| Cultural Diversity | 1 | 2005 | 16 | 0.060 |
Why?
|
| Dietary Supplements | 1 | 2005 | 44 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2024 | 22 | 0.050 |
Why?
|
| Obesity | 2 | 2007 | 226 | 0.050 |
Why?
|
| Trabeculectomy | 1 | 2024 | 40 | 0.050 |
Why?
|
| Heart Rate | 1 | 2003 | 29 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2023 | 21 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2022 | 13 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2022 | 13 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2021 | 66 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 87 | 0.040 |
Why?
|
| Chronic Disease | 3 | 2006 | 167 | 0.040 |
Why?
|
| Machine Learning | 1 | 2020 | 12 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 127 | 0.040 |
Why?
|
| Trauma Centers | 1 | 2019 | 7 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2020 | 197 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 2 | 2014 | 115 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2019 | 15 | 0.040 |
Why?
|
| DNA Damage | 1 | 2019 | 20 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2019 | 19 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2019 | 14 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 64 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2019 | 143 | 0.030 |
Why?
|
| Health Expenditures | 1 | 2018 | 16 | 0.030 |
Why?
|
| Diet | 1 | 2019 | 111 | 0.030 |
Why?
|
| Fractures, Bone | 1 | 2018 | 21 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2018 | 109 | 0.030 |
Why?
|
| Poisoning | 1 | 2017 | 7 | 0.030 |
Why?
|
| Wounds, Penetrating | 1 | 2017 | 9 | 0.030 |
Why?
|
| Age Distribution | 1 | 2017 | 45 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2017 | 44 | 0.030 |
Why?
|
| Triglycerides | 2 | 2007 | 58 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2016 | 7 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2016 | 6 | 0.030 |
Why?
|
| Social Norms | 1 | 2016 | 4 | 0.030 |
Why?
|
| Cell Phone | 1 | 2016 | 6 | 0.030 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2016 | 13 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2016 | 27 | 0.030 |
Why?
|
| Attitude | 1 | 2016 | 15 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 24 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 57 | 0.030 |
Why?
|
| Students | 1 | 2016 | 40 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2016 | 77 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 156 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2006 | 104 | 0.030 |
Why?
|
| Stroke | 1 | 2016 | 46 | 0.030 |
Why?
|
| Free Radicals | 1 | 2015 | 3 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2015 | 19 | 0.030 |
Why?
|
| Organ Size | 1 | 2015 | 31 | 0.030 |
Why?
|
| Rats | 1 | 2016 | 571 | 0.030 |
Why?
|
| Depression | 1 | 2016 | 128 | 0.030 |
Why?
|
| Cichlids | 1 | 2013 | 2 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2013 | 4 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2013 | 8 | 0.020 |
Why?
|
| Radiation-Protective Agents | 1 | 2013 | 5 | 0.020 |
Why?
|
| Antioxidants | 1 | 2013 | 37 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 111 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 155 | 0.020 |
Why?
|
| Audiometry | 1 | 2012 | 6 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 500 | 0.020 |
Why?
|
| Ethiodized Oil | 1 | 2010 | 3 | 0.020 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2010 | 3 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2010 | 3 | 0.020 |
Why?
|
| alpha-Fetoproteins | 1 | 2010 | 6 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2010 | 9 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2010 | 6 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 23 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 45 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2010 | 101 | 0.020 |
Why?
|
| Ethanol | 1 | 2010 | 86 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2007 | 11 | 0.020 |
Why?
|
| Drug Costs | 1 | 2007 | 11 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2008 | 331 | 0.020 |
Why?
|
| Medicaid | 1 | 2007 | 19 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2007 | 50 | 0.020 |
Why?
|
| Medical Records | 1 | 2007 | 23 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 2006 | 6 | 0.020 |
Why?
|
| Demography | 1 | 2006 | 26 | 0.020 |
Why?
|
| Social Class | 1 | 2007 | 46 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2006 | 23 | 0.020 |
Why?
|
| Cholesterol | 1 | 2006 | 37 | 0.020 |
Why?
|
| Indians, North American | 1 | 2005 | 5 | 0.010 |
Why?
|
| Education | 1 | 2005 | 11 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 54 | 0.010 |
Why?
|
| Osteoporosis | 1 | 2005 | 12 | 0.010 |
Why?
|
| Data Collection | 1 | 2005 | 38 | 0.010 |
Why?
|
| Minority Groups | 1 | 2005 | 63 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 16 | 0.010 |
Why?
|
| Kidney | 1 | 2005 | 184 | 0.010 |
Why?
|
| Body Weight | 1 | 2003 | 90 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 2002 | 9 | 0.010 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2005 | 293 | 0.010 |
Why?
|